Financial Ratios Carl Zeiss Meditec AG
Equities
AFX
DE0005313704
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.04 EUR | -1.34% |
|
-7.67% | -37.40% |
| 03-05 | Lufthansa Narrowly Misses Return to DAX | RE |
| 03-04 | INDEX MONITOR: Lufthansa Misses Out on DAX Comeback – Changes Only in MDAX and SDAX | DP |
| Fiscal Period: September | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 10.5 | 9.55 | 7.55 | 3.65 | 4.11 | |||||
Return on Total Capital | 13.95 | 12.6 | 9.85 | 4.74 | 5.29 | |||||
Return On Equity % | 15.19 | 15.96 | 13.9 | 8.52 | 6.8 | |||||
Return on Common Equity | 15.29 | 16 | 13.91 | 8.51 | 6.79 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 58.73 | 59.26 | 57.71 | 52.69 | 52.76 | |||||
SG&A Margin | 22.15 | 22.98 | 24.07 | 27.01 | 28.13 | |||||
EBITDA Margin % | 23.62 | 22.05 | 17.96 | 10.89 | 12.29 | |||||
EBITA Margin % | 22.58 | 21.01 | 16.99 | 9.66 | 11.08 | |||||
EBIT Margin % | 22.49 | 20.96 | 16.93 | 9.07 | 10.02 | |||||
Income From Continuing Operations Margin % | 14.42 | 15.55 | 13.98 | 8.72 | 6.39 | |||||
Net Income Margin % | 14.35 | 15.45 | 13.9 | 8.65 | 6.34 | |||||
Net Avail. For Common Margin % | 14.35 | 15.45 | 13.9 | 8.65 | 6.34 | |||||
Normalized Net Income Margin | 12.77 | 11.47 | 11.95 | 5.65 | 5.26 | |||||
Levered Free Cash Flow Margin | 3.6 | 6.98 | 3.68 | 38.24 | 3.92 | |||||
Unlevered Free Cash Flow Margin | 3.93 | 7.28 | 4.13 | 39.13 | 4.67 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.75 | 0.73 | 0.71 | 0.64 | 0.66 | |||||
Fixed Assets Turnover | 11.08 | 10.05 | 9.25 | 8.03 | 8.1 | |||||
Receivables Turnover (Average Receivables) | 5.64 | 5.15 | 5 | 4.81 | 4.65 | |||||
Inventory Turnover (Average Inventory) | 2.37 | 2.32 | 1.96 | 1.85 | 2.04 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3.58 | 3.32 | 3.4 | 2.13 | 2.35 | |||||
Quick Ratio | 2.9 | 2.55 | 2.33 | 1.06 | 1.32 | |||||
Operating Cash Flow to Current Liabilities | 0.81 | 0.35 | 0.45 | 0.43 | 0.39 | |||||
Days Sales Outstanding (Average Receivables) | 64.7 | 70.94 | 73 | 76.13 | 78.56 | |||||
Days Outstanding Inventory (Average Inventory) | 153.81 | 157.52 | 186.52 | 197.84 | 179.26 | |||||
Average Days Payable Outstanding | 63.68 | 70.07 | 76.68 | 77.95 | 68.03 | |||||
Cash Conversion Cycle (Average Days) | 154.83 | 158.39 | 182.84 | 196.03 | 189.79 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 7.23 | 6.3 | 7.17 | 26.93 | 25.14 | |||||
Total Debt / Total Capital | 6.74 | 5.93 | 6.69 | 21.22 | 20.09 | |||||
LT Debt/Equity | 6.08 | 5.24 | 6.16 | 25.61 | 23.89 | |||||
Long-Term Debt / Total Capital | 5.67 | 4.93 | 5.75 | 20.18 | 19.09 | |||||
Total Liabilities / Total Assets | 29.99 | 28.08 | 28.36 | 39.39 | 37.48 | |||||
EBIT / Interest Expense | 43.18 | 43.84 | 23.19 | 6.37 | 8.39 | |||||
EBITDA / Interest Expense | 47.53 | 48.27 | 26.15 | 8.55 | 11.25 | |||||
(EBITDA - Capex) / Interest Expense | 44.02 | 43.56 | 21.84 | 5.6 | 9.77 | |||||
Total Debt / EBITDA | 0.3 | 0.29 | 0.39 | 2.2 | 1.79 | |||||
Net Debt / EBITDA | 0.28 | 0.27 | 0.36 | 2.12 | 1.7 | |||||
Total Debt / (EBITDA - Capex) | 0.32 | 0.32 | 0.47 | 3.36 | 2.06 | |||||
Net Debt / (EBITDA - Capex) | 0.3 | 0.3 | 0.44 | 3.24 | 1.95 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 23.31 | 15.55 | 9.8 | -1.11 | 7.82 | |||||
Gross Profit, 1 Yr. Growth % | 29.74 | 16.58 | 6.93 | -9.71 | 7.95 | |||||
EBITDA, 1 Yr. Growth % | 94.43 | 7.85 | -10.27 | -39.29 | 27.41 | |||||
EBITA, 1 Yr. Growth % | 104.94 | 7.51 | -10.95 | -43.04 | 30.33 | |||||
EBIT, 1 Yr. Growth % | 109.34 | 7.69 | -11.07 | -46.31 | 26.01 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 92.45 | 24.58 | -1.32 | -38.31 | -20.99 | |||||
Net Income, 1 Yr. Growth % | 93.06 | 24.39 | -1.2 | -38.45 | -20.99 | |||||
Normalized Net Income, 1 Yr. Growth % | 118.52 | 3.8 | 14.83 | -52.67 | 6.08 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 93.06 | 24.39 | -1.2 | -38.05 | -19.8 | |||||
Accounts Receivable, 1 Yr. Growth % | 24.26 | 28.63 | 1.73 | 3.95 | 18.88 | |||||
Inventory, 1 Yr. Growth % | 0.01 | 33.65 | 35.92 | 3.14 | -7.33 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 48.12 | 13.48 | 24.52 | 5.28 | 8.32 | |||||
Total Assets, 1 Yr. Growth % | 18.92 | 17.82 | 7.44 | 11.88 | 0.3 | |||||
Tangible Book Value, 1 Yr. Growth % | 21.32 | 19.47 | 10.22 | -56.38 | 14.86 | |||||
Common Equity, 1 Yr. Growth % | 15.9 | 21.44 | 7.16 | -5.45 | 3.66 | |||||
Cash From Operations, 1 Yr. Growth % | 103.14 | -48.11 | 33.3 | -1.41 | -15.15 | |||||
Capital Expenditures, 1 Yr. Growth % | 2.72 | 42.1 | 53.38 | 32.24 | -54.62 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -1.6 | 124.03 | -41.84 | 968.78 | -88.86 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -16.36 | 114.25 | -37.32 | 868.76 | -87.04 | |||||
Dividend Per Share, 1 Yr. Growth % | 80 | 22.22 | 0 | -45.45 | -8.33 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 6.23 | 19.37 | 12.64 | 4.2 | 3.26 | |||||
Gross Profit, 2 Yr. CAGR % | 7.83 | 22.98 | 11.65 | -1.74 | -1.28 | |||||
EBITDA, 2 Yr. CAGR % | 17.02 | 44.81 | -1.77 | -26.65 | -14.07 | |||||
EBITA, 2 Yr. CAGR % | 17.55 | 48.43 | -2.3 | -29.24 | -16.07 | |||||
EBIT, 2 Yr. CAGR % | 18.42 | 50.15 | -2.28 | -31.35 | -20.02 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 21.62 | 54.84 | 10.88 | -21.97 | -30.18 | |||||
Net Income, 2 Yr. CAGR % | 21.61 | 54.97 | 10.86 | -22.02 | -30.27 | |||||
Normalized Net Income, 2 Yr. CAGR % | 21.32 | 50.61 | 8.97 | -26.7 | -31.1 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 21.61 | 54.97 | 10.86 | -21.76 | -29.51 | |||||
Accounts Receivable, 2 Yr. CAGR % | 0.02 | 26.43 | 14.14 | 2.84 | 11.17 | |||||
Inventory, 2 Yr. CAGR % | 3.31 | 15.61 | 34.78 | 18.4 | -2.24 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 26.34 | 29.65 | 18.87 | 14.5 | 6.79 | |||||
Total Assets, 2 Yr. CAGR % | 8.85 | 18.36 | 12.51 | 9.64 | 5.93 | |||||
Tangible Book Value, 2 Yr. CAGR % | 12.82 | 20.39 | 14.75 | -30.66 | -29.22 | |||||
Common Equity, 2 Yr. CAGR % | 8.93 | 18.64 | 14.08 | 0.66 | -1 | |||||
Cash From Operations, 2 Yr. CAGR % | 28.5 | 2.67 | -16.83 | 14.64 | -8.54 | |||||
Capital Expenditures, 2 Yr. CAGR % | 21.67 | 20.82 | 47.63 | 42.41 | -22.54 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -41.25 | 48.47 | 13.83 | 144.6 | 8.67 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -39.49 | 33.86 | 15.57 | 142.27 | 11.59 | |||||
Dividend Per Share, 2 Yr. CAGR % | 17.67 | 48.32 | 10.55 | -26.15 | -29.29 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 8.74 | 9.25 | 16.09 | 7.85 | 5.39 | |||||
Gross Profit, 3 Yr. CAGR % | 10.83 | 10.67 | 17.38 | 4.02 | 1.39 | |||||
EBITDA, 3 Yr. CAGR % | 21.35 | 13.88 | 23.34 | -16.67 | -13.18 | |||||
EBITA, 3 Yr. CAGR % | 23 | 14.1 | 25.06 | -18.74 | -14.77 | |||||
EBIT, 3 Yr. CAGR % | 23.52 | 14.73 | 25.97 | -20.31 | -17.5 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 23.46 | 22.6 | 33.25 | -8.8 | -21.65 | |||||
Net Income, 3 Yr. CAGR % | 23.16 | 22.53 | 33.38 | -8.89 | -21.68 | |||||
Normalized Net Income, 3 Yr. CAGR % | 23.86 | 15.17 | 37.41 | -17.79 | -18.63 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 23.16 | 22.53 | 33.38 | -8.68 | -21.11 | |||||
Accounts Receivable, 3 Yr. CAGR % | 3.61 | 8.77 | 17.42 | 10.64 | 7.93 | |||||
Inventory, 3 Yr. CAGR % | 4.9 | 12.57 | 22.02 | 23.28 | 9.11 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 45.71 | 21.9 | 27.92 | 14.16 | 12.4 | |||||
Total Assets, 3 Yr. CAGR % | 12.97 | 11.76 | 14.61 | 12.3 | 6.43 | |||||
Tangible Book Value, 3 Yr. CAGR % | 6.85 | 14.99 | 16.9 | -16.88 | -17.96 | |||||
Common Equity, 3 Yr. CAGR % | 8.66 | 12.95 | 14.68 | 7.16 | 1.65 | |||||
Cash From Operations, 3 Yr. CAGR % | 24.66 | -5.02 | 12.01 | -11.98 | 3.7 | |||||
Capital Expenditures, 3 Yr. CAGR % | 22.13 | 28.13 | 30.82 | 42.31 | -2.73 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 16.16 | -8.21 | 8.43 | 137.1 | -12.88 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 18.24 | -7.77 | 3.76 | 132.13 | -8.96 | |||||
Dividend Per Share, 3 Yr. CAGR % | 17.84 | 19.17 | 30.06 | -12.64 | -20.63 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 8.64 | 9.84 | 10.28 | 7.2 | 10.78 | |||||
Gross Profit, 5 Yr. CAGR % | 10.79 | 11.42 | 11.16 | 5.53 | 9.53 | |||||
EBITDA, 5 Yr. CAGR % | 18.17 | 17.1 | 11.51 | -4.55 | 6.47 | |||||
EBITA, 5 Yr. CAGR % | 18.92 | 17.87 | 12.18 | -5.8 | 6.34 | |||||
EBIT, 5 Yr. CAGR % | 19.36 | 18.28 | 12.47 | -6.63 | 4.76 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 18.9 | 16.86 | 18.26 | 2.33 | 2.89 | |||||
Net Income, 5 Yr. CAGR % | 19.16 | 16.93 | 18.09 | 2.27 | 2.9 | |||||
Normalized Net Income, 5 Yr. CAGR % | 19.27 | 14.3 | 17.67 | -3.95 | 4.01 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 16.91 | 15.91 | 18.09 | 2.4 | 3.35 | |||||
Accounts Receivable, 5 Yr. CAGR % | 5.11 | 7.68 | 7.7 | 6.26 | 14.88 | |||||
Inventory, 5 Yr. CAGR % | 6.57 | 10.31 | 15.96 | 14.87 | 11.67 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 22.89 | 28.96 | 34.31 | 18.88 | 19 | |||||
Total Assets, 5 Yr. CAGR % | 13.94 | 11.7 | 12.78 | 10.91 | 11.05 | |||||
Tangible Book Value, 5 Yr. CAGR % | 16.73 | 9.22 | 9.95 | -6.07 | -4.36 | |||||
Common Equity, 5 Yr. CAGR % | 15.77 | 10.64 | 10.79 | 7.86 | 8.13 | |||||
Cash From Operations, 5 Yr. CAGR % | 26.54 | 37.91 | 6.03 | 2.4 | 3.29 | |||||
Capital Expenditures, 5 Yr. CAGR % | 18.68 | 25.67 | 31.76 | 33.66 | 6.08 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -2.67 | -10.19 | 15.22 | 35.7 | 7.7 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -0.58 | -9.35 | 17.16 | 35.57 | 6.1 | |||||
Dividend Per Share, 5 Yr. CAGR % | 16.47 | 14.87 | 14.87 | -1.59 | 1.92 |
- Stock Market
- Equities
- AFX Stock
- Financials Carl Zeiss Meditec AG
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















